A major focus is sample size, including our Lancet Digital Health paper on AI-based prediction models.
It's 15 years since a few of us started the group because we thought prognosis reviews were important.
UK methodology funding is sparse, so on the MRC-NIHR panel I help make sure strong methods work gets funded.
Join live or work through it over 2-3 weeks, with practicals in R or Stata. I run one on IPD meta-analysis too.
I conceived it, ran the analyses and wrote it up, usually at the weekend after watching the boxsets.
We began in 2014, a long road, and it's rewarding to see it now helping others on their IPD projects.
It grew out of PROGRESS, and its companion site, prognosisresearch.com, is one I run with Kym Snell.
Harry Hemingway, Doug Altman and I met unfunded for about 3 years, worried by poor prognosis research.
Professor of Biostatistics at University of Birmingham
I research and teach statistical methods for prognosis, prediction models and meta-analysis in healthcare.
A major focus is sample size, including our Lancet Digital Health paper on AI-based prediction models.
It's 15 years since a few of us started the group because we thought prognosis reviews were important.
UK methodology funding is sparse, so on the MRC-NIHR panel I help make sure strong methods work gets funded.
Join live or work through it over 2-3 weeks, with practicals in R or Stata. I run one on IPD meta-analysis too.
I conceived it, ran the analyses and wrote it up, usually at the weekend after watching the boxsets.
We began in 2014, a long road, and it's rewarding to see it now helping others on their IPD projects.
It grew out of PROGRESS, and its companion site, prognosisresearch.com, is one I run with Kym Snell.
Harry Hemingway, Doug Altman and I met unfunded for about 3 years, worried by poor prognosis research.
Professor of Biostatistics at University of Birmingham
I research and teach statistical methods for prognosis, prediction models and meta-analysis in healthcare.
A major focus is sample size, including our Lancet Digital Health paper on AI-based prediction models.
It's 15 years since a few of us started the group because we thought prognosis reviews were important.
UK methodology funding is sparse, so on the MRC-NIHR panel I help make sure strong methods work gets funded.
Join live or work through it over 2-3 weeks, with practicals in R or Stata. I run one on IPD meta-analysis too.
I conceived it, ran the analyses and wrote it up, usually at the weekend after watching the boxsets.
We began in 2014, a long road, and it's rewarding to see it now helping others on their IPD projects.
It grew out of PROGRESS, and its companion site, prognosisresearch.com, is one I run with Kym Snell.
Harry Hemingway, Doug Altman and I met unfunded for about 3 years, worried by poor prognosis research.
By using this service, you agree to the Terms of Service and Privacy Policy.